Investor Presentaiton
Outlook
SL
CSL Behring
.
•
•
Underlying patient.
demand for lg in core
indications remain
strong
2H growth expected
for HEMGENIX®
Plasma and
yield initiatives
ongoing
Gross margin
recovery underway
CSL Seqirus
Progression of
global registrations
for next-
generation mRNA
COVID vaccine
~85% of sales in 1H,
with expenses
falling more evenly
over the year
giving rise to a loss
in 2H, consistent
with seasonality
7
For forward looking statements, refer to Legal Notice on page 2
2
3
4
CSL Vifor
•
.
•
Well positioned for iron
competition
Nephrology launch
momentum
Unlock value across CSL
commercial and
operations e.g. patient
blood management
with CSL Behring
Constant Currency (CC) removes the impact of exchange rate movements to facilitate comparability. See end note for further detail
% growth rates exclude the one-off gain from the sale of property in FY23 (NPATA $44m)
NPATA to NPAT adjustments are estimated to be:
Amortisation of acquired intellectual property. FY24 estimate $320m (pre-tax), $270m (post tax)
CSL Vifor integration costs and the unwind of inventory fair value uplift. FY24 estimate $85m (pre-tax), $70m (post-tax)
FY24 FX impact expected to be a headwind of ~$85M if current rates remain unchanged for the remainder of the financial year
FY24 Guidance
Reaffirmed
Revenue Growth
~ 9-11% @CC²
NPATA Growth
~13-17% @CC2,3 to
~$2.9 - $3.0b @CC24
Driven by Our Promise
19
CSLView entire presentation